The price you pay for Elevidys may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...

Learn more about whether Sarepta Therapeutics, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

Charles Schwab Investment Management Inc. boosted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 2 ...

Learn more about whether Kymera Therapeutics, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

Approved in 2019, it earned over $1.2 billion in annual sales in 2024. Sarepta’s delandistrogene moxeparvovec (Elevidys), approved in 2023 for Duchenne muscular dystrophy, is racking up sales ...

Edgewise Therapeutics' stock soars on positive Becker Muscular Dystrophy trial results. Learn why EWTX is a promising buy with derisked programs.

Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm ...

Elevidys (delandistrogene moxeparvovec) can now be used to treat both ambulatory and non-ambulatory boys aged four and above with DMD, a major expansion on its earlier accelerated approval with a ...

The green light for delandistrogene moxeparvovec – now given the brand name Elevidys – comes after a long and sometimes tortuous path through clinical development and an FDA advisory committee ...